Slate Uses Fulcrum to Join Nasdaq With $245M Financing for Migraine Trials on August 17, 2026 Capital Management Forbion Frazier Life Sciences Fulcrum Therapeutics migraine prevention private placement reverse merger Rheumatoid Arthritis Slate Medicines SLTE +
Slate Medicines Launches with $130M Series A for Anti-PACAP Migraine Drug from China's DartsBio on February 24, 2026 DartsBio methionine Migraine Disorders pituitary adenylate cyclase activating polypeptide Series A Slate Medicines SLTE-1009 +